Prader-Willi Syndrome Patients in a Long-Term Extension to Clinical Trial PC025

Thank you for your support and sharing:

Good news every one! We are almost there. Essentialis Announces the Dosing of the First Prader-Willi Syndrome Patients in a Long-Term Extension to Clinical Trial PC025.
Patients who completed the first two phases of clinical study PC025 are currently being enrolled in a 6-month open label extension.  The objective of the extension is to document the long-term therapeutic benefits of DCCR, Essentialis’ lead drug, on hyperphagia, body fat, lean body mass, aggressive, threatening and destructive behaviors and on stamina.The 6-month extension is being run by Dr. Virginia Kimonis’ team and the staff of the ICTS at the University of California, Irvine.

Link to the article:

http://www.prnewswire.com/news-releases/essentialis-announces-the-dosing-of-the-first-prader-willi-syndrome-patients-in-a-long-term-extension-to-clinical-trial-pc025-300139602.html

About Essentialis

http://essentialistherapeutics.com